MolecularMatch adds advanced search features and machine learning, further solidifying MMPower as oncology’s leading molecular search engine

MolecularMatch Announces New Search Engine v5

Houston – October 1, 2020 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced the release of MMPower version 5 (v5), the latest update to its Clinical Decision Support platform. This new release includes improved and expanded search results as well as the introduction of language support beyond English, starting with Spanish translated medical terms.

Key new features for MolecularMatch’s expanded and improved search results include:

• Auto-correction of misspellings (many clinical terms can now be misspelled and still understood by the MolecularMatch search engine)
• Ontological expansion of search terms (searches will be performed with deeper analysis into the meaning of the search terms)
• Recognition of terms that are not already part of the MolecularMatch vocabulary (AI-based comprehension of unstructured text to classify new concepts, such as novel mutations)
• Additional advanced search features (including literal text search, negative term search, and a “must include” search filter)

MMPower v5 represents a significant advancement in the company’s core search engine platform, introducing AI which augments the pre-existing vocabulary of the MolecularMatch Knowledge Graph (which currently includes over 65 million terms) with a neural network trained to detect never-before-seen concepts and classify them into the appropriate data type (i.e., Condition, Clinical Finding, Gene, Mutation, Drug, etc.).

“Version 5 is a major milestone in the development of our core platform,” said Eric Pulaski, CEO at MolecularMatch. “Our new advanced search features, and incorporation of machine learning, further solidifies MolecularMatch as the leading molecular search engine for oncology, matching each individual patient to the best-fit for clinical trials and therapeutic guidance based on both the genomic and clinical details of each specific case.

About MolecularMatch
MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company established in 2014. The company was founded on the vision of using tumor molecular profiling to provide the best personalized treatment options for cancer patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient’s genomic and clinical details. Customers include genetic labs, health information systems, biopharma, hospitals and cancer centers. Visit us at molecularmatch.com or follow us on Twitter or LinkedIn.

Laura Roberts

MolecularMatch
832-515-7962
lroberts@molecularmatch.com

MolecularMatch appoints Eric Pulaski as President

Pulaski joins executive team to drive product strategy and revenue growth

Houston – June 24, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced today that Eric Pulaski will serve as President for MolecularMatch.

Pulaski has over 30 years of experience across the technology and software sector. Pulaski was most recently the Founder and CEO of SmartVault Corporation, a leading SaaS provider in the online document management and secure portal space. He founded the company in 2007 and ultimately sold it to Reckon Ltd in 2016. He was the founder and CEO of BindView, where he grew that company into a leading, global Internet Security company with over $70M in revenues and 650 employees, and later sold to Symantec for over $200M. Pulaski also founded and served as CEO for several other tech companies, including RedFlag Software and Lightbulb Technology Partners.

As a serial entrepreneur, Eric’s specialties are developing and executing product strategy, building and retaining high-performing teams during high-growth and change, evangelism and communication, and managing shareholder and investor relationships.

“Eric’s experience as a seasoned entrepreneur, especially as it relates to software businesses, makes him the perfect choice in leading MolecularMatch through a very unique period for our company,” said James W. Welsh, MD, Founder at MolecularMatch. “I am confident he will spearhead strategic initiatives that will help us accelerate growth.”

Pulaski said: “MolecluarMatch is a visionary company with a vibrant culture at the forefront of innovation in the heart of the Texas Medical Center. I look forward to working closely with Jim and the leadership team to capitalize on the enormous market opportunities in front of us.”

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company founded in 2014 out of MD Anderson Cancer Center. The company was founded on the vision of using tumor molecular profiling, and outcomes from previously-treated patients, to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals and cancer centers. Visit us at molecularmatch.com